'VOI. 86, NO 10, Supplement
`
`l
`
`(0
`
`NOVEMBER 15, 1995
`
`T BRA E. & co APANY
`
`Celflrinn, Inc. 11111
`Galltriunvfianantach
`
`'
`
`-
`
`.
`
`IPPJD'1?-D'l'122
`
`A U N D E R S
`ON OF
`
`f.
`
`,
`C O M P A N Y
`—
`
`
`1305
`
`LlndenDrlvaManson,WI53706
`
`If)
`H.—
`
`mC
`
`O N >O2
`
`E«
`
`:5ecu;
`a:
`
`38tn
`‘0.—
`m7
`(.9)
`5‘6
`52‘
`6°17,
`76
`E:
`El:
`MD2
`
`American Society of Hematology
`Thirty-Seventh Annual Meeting
`December 1-5, 1995
`Seattle, WA
`
`1 of 11
`
`

`

`BLOOD
`
`HEALIH SCIENCES LIBRARY
`University of Wisconsin
`
`Thejozmeezl of
`The American Society ofHmatology
`
`1305 Llnden Drive
`Madison. WI 53706
`
`
`
`
`NOV 20 1995
`
`Blood: The Journal of The American Society of Hematol-
`ogy (ISSN 0006-4971) is published 25 times, in two volumes
`per year, by W.B. Saunders Company. Dates of issue are
`the first and the 15th of each month except November in
`which three issues will be published. W.B. Saunders Com-
`pany Corporate and Editorial Offices: The Cunis Center,
`Independence Square West, Philadelphia, PA l9IO6-3399.
`Accounting and Circulation Offices: W.B. Saunders Com-
`pany, Periodicals Dept.. 6277 Sea Harbor Dr. Orlando, FL
`32887-4800. Second class postage paid at Orlando, FL
`32862, and at additional mailing offices.
`POSTMASTER: Send change of address to Blood: The
`Journal of The American Society of Hematology, c/o W.B.
`Saunders Company, Periodicals Dept. 6277 Sca Harbor Dr.
`Orlando. FL 32887-4800.
`Editorial correspondence should be addressed to:
`James D. Griffin, MD. Editor-in-Chicf
`BLOOD
`
`The Journal of The American Society
`of Hematology
`1018 Beacon Street
`Brookline. MA 02146
`Correspondence regarding subscriptions or change of
`address should be addressed to W.B. Saunders Company.
`Periodicals Dept. 6277 Sea Harbor Dr, Orlando, FL 32887-
`4800.
`Customer Service: 1-800-654—2452.
`Change of address notices, including both the old and
`new addresses of the subscriber. should be sent at least one
`month in advance.
`
`Saunders Company and sent to Blood: The Journal of The
`American Society of Hematology. W.B. Saunders Company,
`Periodicals Dept.. 6277 Sea Harbor Dr, Orlando. FL 32887-
`4800.
`
`Agents for the United Kingdom. Ireland. and Europe: Har—
`court Brace & Company Ltd. 24-28 Oval Rd. London NW1
`7DX. England. Agents for Australia and New Zealand:
`Harcourt Brace & Company Australia, 30-52 Smidmorc St
`(Locked Bag 16). Manickviile. NSW 2204, Australia.
`Agents for Japan and Korea: Harcourt Brace Japan. Inc.
`Ichibancho Central Bldg, 22-1 Ichibancho. Chiyoda-Ku,
`Tokyo 102, Japan.
`Copyright © 1995. The American Society of Hematology.
`All rights reserved. No part of this publication may be repro-
`duced or transmitted in any form or by any means, electronic
`or mechanical, including photocopy. recording. or any infor-
`mation storage and retrieval system, without pemtission in
`writing from the publisher. Printed in the United States of
`America.
`
`Correspondence regarding permission to reprint all or
`part of any article published in this journal should be ad-
`dressed to Journal Permissions Dept., W.B. Saunders Co..
`Orlando, FL 32887. Telephone number 1-407-345-2500.
`Other correspondence (copyediting. production) should
`be addressed to:
`BLOOD
`
`W.B. Saunders Company
`The Curtis Center
`Independence Square West
`Philadelphia, PA 19106-3399
`The appearance of the code at the bottom of the first page
`of an article in this joumal indicates the copyright owner's
`consent that copies of the article may be made for personal
`or internal use. or for the personal or internal use of specific
`clients. This consent is given on the condition, however, that
`the copier pay the stated per-copy fee through the Copyright
`Clearance Center. Inc. (222 Rosewood Dr. Danvers. MA
`01923) for copying beyond that pemiittcd by Sections 107
`or 108 of the US Copyright law. This consent does not
`extend to other kinds of copying. such as copying for general
`distribution. for advertising or promotional purposes. for cre-
`ating new collective works. or for resale. Absence of the
`code indicates that the material may not be processed through
`the Copyright Clearance Center. Inc.
`Advertising Representative: Cunningham Associates.
`PO Box 308. Park Ridge. NJ 07656.
`telephone (201)
`767—4170.
`
`Yearly subscription rates: United States and posses-
`sions: individual, $306.00; institution, $430.00; single is—
`sues. $21.00. All other countries: individual. $445.00; insti-
`tution, $497.00; single issues, $21.00. For all areas outside
`the United States and possessions,
`there is no additional
`charge for surface delivery. For air mail delivery. add
`$144.00. Student and resident: United States and posses-
`sions; $157.00; all other countries: $428.00. To receive
`student/resident rate, orders must be accompanied by name
`of affiliated institution, date of term, and the signature of
`program/residency coordinator on institution letterhead.
`Orders will be billed at individual rate until proof of status
`is received. Back issue and back volume prices are those
`in current effect. Single issues. both current and back. exist
`in limited quantities and are offered for sale subject
`to
`availability. Back issues sold in conjunction with a sub-
`scription are on a prorated basis. Subscriptions are accepted
`on a calendar year basis.
`I994 bound volume price:
`Publication of an advertisement in Blood does not imply
`$105.00; outside US. please add $40.00 for postage. To
`endorsement of its claims by The American Society of He-
`purchase a 1994 bound volume. customer must be a sub-
`matology or by the Editors or Publisher of the joumal.
`scriber for 1994. Cumulative Index (1980—1989) price:
`Every effort has been made to check generic and trade
`$125.00: outside US, please add $2.25 for surface delivery,
`names. and to verify drug doses. The ultimate responsibility.
`or $8.00 for air mail delivery. Prices are subject to change
`however. lies with the prescribing physician. Please convey
`any errors to the Editors.
`without notice. Checks should be made payable to W.B.
`
`
`The American Society of Hematology certifies that the continuing medical education ofi‘ering provided by
`BLOOD. The Journal of The American Society of Hematology, meets the criteria for up to 22 hours of credit
`in Category 5(a) for the Physician '3 Recognition Award of the American Medical Association.
`
`(0 1905. The American Society of Hematology. %
`
`Philadelphia, PA
`
`A Division of Harcourt Brace & Company
`
`20f11
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`
`|PR2017-01122
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`IPR2017-01122
`
`2 of 11
`
`

`

`’/ iii/72
`3,12
`
`BLOOD
`The Journal of The American Society of Hematology
`Editor-in-Chief: James D. Griffin, Boston, MA
`
`Frederick R. Appelbaum, Seattle. WA
`Laurence A. Boxer, Ann Arbor, M]
`H. Franklin Bunn, Boston. MA
`Michael L. Cleary, Stanford, CA
`Connie J. Eaves, Vancouver, BC
`
`Associate Editors
`
`Tucker W. LeBien, Minneapolis, MN
`J. Evan Sadler. St. Louis, MO
`Sanford J. Shattil. La Jolla, CA
`Neal S. Young, Bethesda, MD
`
`Managing Editor: Ken G. Komfield, Brookline, MA
`
`EDITORIAL BOARD
`
`Nader G. Abraham. New York, NY
`Neil Abramson. Jacksonville. FL
`Peter Agre, Baltimore. MD
`Kenneth C. Anderson. Boston, MA
`Joseph H. Antin. Boston. MA
`James 0. Armitage, Omaha, NE
`Jane E. Barker, Bar Harbor, ME
`Joel S. Bennett, Philadelphia, PA
`Nancy Berliner, New Haven. CT
`Alan Bernstein, Toronto, ON
`
`Bruce R. Blazar. Minneapolis, MN
`David M. Bodine, Bethesda, MD
`Dario Campana, Memphis, TN
`Jaime Caro, Philadelphia, PA
`Peter A. Cassileth, Miami, FL
`William M. Crist, Memphis. TN
`Alan D’Andrea, Boston, MA
`Albert B. Deisseroth, Houston. TX
`David N. Fass, Rochester. MN
`Stephen J. Forman, Duarte, CA
`Barbara Furie, Boston, MA
`Janice L. Gabrilove, New York. NY
`Tomas Ganz, Los Angeles, CA
`Mark Ginsberg, La Jolla, CA
`David Ginsburg, Ann Arbor, MI
`Mark A. Goldberg, Boston, MA
`John M. Goldman, London, UK
`Peter L. Greenberg, Stanford, CA
`John M. Harlan, Seattle, WA
`David E. Harrison, Bar Harbor. ME
`Ronald Hoffman, Indianapolis, IN
`Thomas H. Howard, Birmingham, AL
`James Ihle, Memphis, TN
`Russel Kaufman, Durham, NC
`
`Kenneth Kaushansky. Seattle. WA
`John H. Kehrl, Bethesda, MD
`Thomas J. Kipps, La Jolla, CA
`Tadamitsu Kishimoto, Osaka, Japan
`Daniel M. Knowles, New York, NY
`Richard A. Larson, Chicago, IL
`Timothy J. Ley, St. Louis, MO
`Jack Levin, San Francisco, CA
`Dan L. Longo, Frederick. MD
`Bob Lowenberg, Rotterdam. The Netherlands
`Paul J. Martin, Seattle, WA
`
`Rodger P. McEver, Oklahoma City. OK
`Phillip McGlave, Minneapolis, MN
`Robert McMillan, La Jolla, CA
`Jay E. Menitove, Cincinnati. OH
`Donald Metcalf. Melbourne, Australia
`Joseph P. Miletich. St. Louis, MO
`Ronald L. Nagel, Bronx. NY
`Peter J. Newman, Milwaukee, WI
`Robertson Parkman, Los Angeles, CA
`Gordon L. Phillips, lexington. KY
`Mortimer Poncz, Philadelphia, PA
`Ching-Hon Pui, Memphis, TN
`Jerome Ritz, Boston. MA
`Paul N. Sondel, Madison, WI
`Robert F. Todd III, Ann Arbor, MI
`Douglas M. Tollefsen, St. Louis, MO
`Paula B. Tracy, Burlington. VT
`Fatih M. Uckun, Minneapolis, MN
`Catherine M. Verfaillie, Minneapolis, MN
`Stephen J. Weiss, Ann Arbor, MI
`David A. Williams, Indianapolis, IN
`Cheryl L. Willman, Albuquerque, NM
`
`PAST EDITORS
`
`William Dameshek (1946—1969)
`Frederick Stohlman, Jr (l970—l974)
`Ernst R. Jaffé (1975—1977)
`Paul A. Marks (1978—1982)
`John W. Adamson (1983—1987)
`Arthur W. Nienhuis (1988—1992)
`
`3of11
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`
`|PR2017-01122
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`IPR2017-01122
`
`3 of 11
`
`

`

`V
`
`CONTENTS
`
`
`
`
`
`VOL 86, NO 10, Suppl 1 NOVEMBER 15, 1995 CONTENTS
`
`
`
`The Journal of The American Society of Hematology
`
`COVER FIGURE
`
`Cover figure is Sun Mask by James Bender. courtesy of Bailey Nelson Gallery. Seattle. WA.
`
`The American Society of Hematology. I995 ......................................................
`
`..
`
`The American Society of Hematology: Officers of the Society Since [ts Founding ...................
`
`.............................................
`
`
`Standing Committees. 1995 .......................................................................................................................................
`
`Scientific Subcommittees. 1995 .......................................................................................................................
`Recipients of Awards .....................................................................................................................................................
`
`2
`
`3
`
`4
`
`S
`
`6
`
`7
`
`8
`
`9
`
`9
`
`10
`
`12
`
`‘l8
`
`22
`
`23
`
`24
`
`25
`
`26
`
`33
`
`34
`
`37
`
`38
`
`39
`
`40
`
`43
`
`45
`
`46
`
`Reviewers of Abstracts ...................................................................................................................................................
`
`Acknowledgments ...........................................................................................................................................................
`
`Future Meeting Sites ......................................................................................................................................................
`
`National Office ...............................................................................................................................................................
`
`Corporate/Institutional Symposia ...................................................................................................................................
`
`Master Schedule .............................................................................................................................................................
`
`General Information .......................................................................................................................................................
`Maps of Washington State Convention & Trade Center
`
`Levels 1, 2, and 3 .......................................................................................................................................................
`
`Level 4 ........................................................................................................................................................................
`
`Level 6 ........................................................................................................................................................................
`
`Education Program at a Glance .....................................................................................................................................
`
`Program of the Education Committee ....................................................................................................
`
`
`Scientific Subcommittee Program at-a-Glance ..............................................................................................................
`
`Scientific Subcommittee Program ..........................................................................................
`
`Special Lectures .....................................................................................................................................
`
`Meet-the-Professor ...................................................................................................................................
`
`Meet-the-Investigator ........................................................................................................................................
`I995 Invited Speaker Index ...........................................................................................................................................
`
`SATURDAY, DECEMBER 2, 1995
`
`Day-at-a-Glance ....................................................................................................................
`
`Education Program ......................................................................................................................................
`Ham—Wasserman Lecture ...............................................................................................................................................
`
`( Continued on following page)
`
`4 Of 11
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`|PR2017-01122
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`IPR2017-01122
`
`4 of 11
`
`

`

`Vi
`
`(Contents continued)
`
`CONTENTS
`
`
`Education Program ................................................................................................................................................. 46
`Subcommittees .................................................................................................................
`46
`
`Council on Thrombosis ...................................................................................................................................
`
`Welcome Reception ........................................................................................................................................................
`Poster Session I
`
`48
`
`48
`
`Hemoglobinopathies and Thalassemias I ...................................................................................................................
`
`Hematopoietic Cell Proliferation and Differentiation I .............................................................................................
`
`Hematopoietic Growth Factors 1 ................................................................................................................................
`
`Granulocytes and Monocytes l
`
`..................................................................................................................................
`
`Molecular Oncology 1
`
`................................................................................................................................................
`
`Acute Leukemia l .......................................................................................................................................................
`
`Myelodysplasia and Myeloproliferative Disorders I
`
`.................................................................................................
`
`Lymphoma I
`
`...............................................................................................................................................................
`
`Myeloma and CLL I ...................................................................................................................................................
`
`Immunohematology I
`
`.................................................................................................................................................
`
`Coagulation I ..............................................................................................................................................................
`
`Platelets and Megakaryocytes l ..................................................................................................................................
`
`Thrombosis I ...............................................................................................................................................................
`
`Transplantation—Clinical Results l
`
`Transplantation—Clinical CareI
`
`Transplantation—Experimental I
`
`...........................................................................................................................
`
`...............................................................................................................................
`
`Transplantation—Cell Processing I
`
`...........................................................................................................................
`
`SUNDAY, DECEMBER 3, 1995
`
`Day-at-a-Glance ..............................................................................................................................................................
`Education Program ....................................................................................................................................
`
`Subcommittees ............................................................................................................................
`
`
`Plenary Session ....................................................................
`.
`.............................................................................
`Forum on the Practice of Hematology .........................................................................................................................
`Poster Session II
`
`Anemias I ...............................................................................................................................................................
`
`Ancmias II ..................................................................................................................................................................
`
`Hemoglobinopathies and Thalassemias II
`
`.................................................................................................................
`
`Hematopoietic Cell Proliferation and Differentiation [I
`
`...........................................................................................
`
`Hematopoietic Growth Factors II ..............................................................................................................................
`
`Lymphocytes and Immunology I
`
`...............................................................................................................................
`
`49
`
`50
`
`52
`
`53
`
`55
`
`56
`
`58
`
`60
`
`61
`
`62
`
`63
`
`66
`
`66
`
`68
`
`70
`
`72
`
`74
`
`76
`77
`77
`
`80
`
`80
`
`8|
`
`81
`
`83
`
`84
`
`86
`
`8?
`
`5 0f 11
`
`(Continued on following page)
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`|PR2017-01122
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`IPR2017-01122
`
`5 of 11
`
`

`

`CONTENTS
`
`(Contents continued)
`
`Molecular Oncology II ...............................................................................................................................................
`
`Acute Leukemia II ......................................................................................................................................................
`
`Acute Leukemia III ....................................................................................................................................................
`
`Lymphoma I]
`
`..............................................................................................................................................................
`
`Myeloma and CLL II
`
`.................................................................................................................................................
`
`Coagulation [I .............................................................................................................................................................
`
`Thrombosis II
`
`.............................................................................................................................................................
`
`Transplantation—Clinical Results 11 ..........................................................................................................................
`
`Transplantation—Clinical Care I] ..............................................................................................................................
`
`Transplantation—Experimental II ..............................................................................................................................
`
`Transplantation—Cell Processing 11 ..........................................................................................................................
`
`Gene Therapy/Transfer I
`
`............................................................................................................................................
`
`Vii
`
`89
`
`90
`
`91
`
`92
`
`94
`
`95
`
`97
`
`98
`
`100
`
`103
`
`104
`
`106
`
`MONDAY, DECEMBER 4, I995
`
`Day-at—a-Glance ..............................................................................................................................................................
`
`108
`
`Simultaneous Sessions
`
`Anemias I ....................................................................................................................................................................
`
`Hemoglobinopathies and Thalassemias I ...................................................................................................................
`
`Hemoglobinopathies and Thalassemias II
`
`.................................................................................................................
`
`Hematopoietic Cell Proliferation and Differentiation I .............................................................................................
`
`Hematopoietic Cell Proliferation and Differentiation II ...........................................................................................
`
`l 10
`
`110
`
`l 11
`
`111
`
`112
`
`Hematopoietic Growth Factors I ..............................................................................................................................
`112
`1 13
`Hematopoietic Growth Factors II .........................................................
`.
`..............
`
`Granulocytes and Monocytes 1 ...........................................................................................
`113
`
`Molecular Oncology I .....................................................................................................
`Molecular Oncology II ...............................................................................................................................................
`
`114
`
`1 l4
`
`Acute Leukemia l
`
`.......................................................................................................................................................
`
`Acute Leukemia II ......................................................................................................................................................
`
`Myelodysplasia and Myeloproliferative Disorders I
`
`.................................................................................................
`
`Lymphoma I ...............................................................................................................................................................
`
`Lymphoma II ..............................................................................................................................................................
`
`Myeloma and CLL I ...................................................................................................................................................
`
`Immunohematology 1
`
`.................................................................................................................................................
`
`Coagulation I ..............................................................................................................................................................
`
`Platelets and Megakaryocytes l ..................................................................................................................................
`
`Platelets and Megakaryocyles [I
`
`................................................................................................................................
`
`Thrombosis I ...............................................................................................................................................................
`
`115
`
`l 16
`
`117
`
`1 18
`
`119
`
`120
`
`120
`
`121
`
`121
`
`122
`
`122
`
`(Continued on following page)
`
`6 0f 11
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`|PR2017-01122
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`IPR2017-01122
`
`6 of 11
`
`

`

`viii
`
`(Contents continued)
`
`CONTENTS
`
`Retroviral Diseases .....................................................................................................................................................
`
`Transplantation—Clinical Results I
`
`...........................................................................................................................
`
`Transplantation—Clinical Care I
`
`...............................................................................................................................
`
`Transplantation—Cell Processing I
`
`...........................................................................................................................
`
`Gene Therapy/Transfer I
`Poster Session [II
`
`............................................................................................................................................
`
`Hemoglobinopathiec and Thalassemias II] ................................................................................................................
`
`Hematopoietic Cell Proliferation and Differentiation Ill ..........................................................................................
`
`Hematopoietic Growth Factors HI .............................................................................................................................
`
`Hematopoietic Growth Factors 1V .............................................................................................................................
`
`Lymphocytes and Immunology II .....
`
`Molecular Oncology III ..................
`
`Acute Leukemia IV .............................................................................
`
`Myelodysplasia and Myeloproliferative Disorders 11 .......................................
`
`
`
`
`Lymphoma III .............................................................................................................................................................
`
`Myeloma and CLL III ................................................................................................................................................
`Transfusion I ...............................................................................................................................................................
`
`Coagulation III ............................................................................................................................................................
`
`................................................................................................................................
`Platelets and Megakaryocytes l'l
`Thrombosis [II ............................................................................................................................................................
`
`Retroviral Diseases I
`
`..................................................................................................................................................
`
`Transplantation—Clinical Results III ........................................................................................................................
`
`Transplantation—Clinical Care [11 .............................................................................................................................
`
`Transplantation—Cell Processing III .........................................................................................................................
`
`Gene Therapy/Transfer II ...........................................................................................................................................
`Simultaneous Sessions
`
`Red Cell Structure and Function ..............................................................................................................................
`
`Hemoglobinopathies and Thalassemias III ................................................................................................................
`
`Hematopoietic Cell Proliferation and Differentiation III ..........................................................................................
`
`Hematopoietic Cell Proliferation and Differentiation IV ..........................................................................................
`
`Hematopoietic Growth Factors III .............................................................................................................................
`
`Granulocytes and Monocytes II
`
`Lymphocytes and Immunology I ..
`
`
`
`............................................................................................
`
`. ........................................................................
`
`Molecular Oncology III .........................................................................................
`
`Molecular Oncology IV .............................................................................................................................................
`Acute Leukemia III
`....................................................................................................................................................
`
`123
`
`123
`
`124
`
`124
`
`125
`
`126
`
`126
`
`128
`
`129
`
`130
`
`131
`
`133
`
`133
`
`135
`
`136
`138
`
`139
`
`140
`I42
`
`144
`
`144
`
`146
`
`149
`
`151
`
`153
`
`153
`
`154
`
`154
`
`155
`
`155
`
`156
`
`156
`
`157
`158
`
`7 0f 11
`
`(Continued on following page)
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`|PR2017-01122
`
`Celltrion, Inc. 1101
`Celltrion v. Genentech
`IPR2017-01122
`
`7 of 11
`
`

`

`CONTENTS
`
`(Contents continued)
`
`Acute Leukemia IV ....................................................................................................................................................
`
`Myelodysplasia and Myeloproliferative Disorders [1 ................................................................................................
`
`Lymphoma III .............................................................................................................................................................
`
`Myeloma and CLL II
`
`.................................................................................................................................................
`
`Immunohematology Il
`
`................................................................................................................................................
`
`Transfusion I ...............................................................................................................................................................
`
`Coagulation II .............................................................................................................................................................
`
`Coagulation III ............................................................................................................................................................
`
`Platelets and Megakaryocytes III ...............................................................................................................................
`
`.............................................................................................................................................................
`
`Platelets and Megakaryocytes IV
`
`Thrombosis II
`
`I Transplantation—Clinical Results H .........................................................................................................